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Summary Sixty-eight patients with advanced breast cancer were treated with mitoxantrone and clinical
responses assessed. Expression of c-erbB-2 protein and cytosolic glutathione S-transferase (GST) isoenzymes
pi, alpha and mu by the primary tumours of these patients was determined immunohistochemically, and
correlated with treatment response. Tumours overexpressing c-erbB-2 (n = 16, 23%) showed a lower response
rate (50% vs 58%) and shorter duration of response to treatment, compared with c-erbB-2 negative tumours.
These associations were not statistically significant but survival following start of treatment was significantly
shorter in the c-erbB-2 positive group. For each GST isoenzyme, the response rate and duration of response of
the group showing enzyme expression did not differ significantly from those with negatively staining tumours.
These data do not support a role for expression of GSTs alone in resistance to mitoxantrone monotherapy
in advanced breast cancer. The poorer post treatment survival of patients with c-erbB-2 positive tumours
suggests they could be selected for more intensive treatment regimens.
In selecting patients with breast cancer for chemotherapy use
is made of characteristics such as lymph node status which
are indicators of prognosis, but not necessarily markers of
the likelihood of response (Mittra, 1990). In contrast, it is
known that response to hormonal therapy of recurrent breast
carcinoma is more likely in those patients whose tumours are
oestrogen-receptor positive (Litherland & Jackson, 1988) or
epidermal growth factor (EGFR) negative (Nicholson et al.,
1989), and in a study of 65 breast cancer patients response to
endocrine therapy on relapse was observed in only one (7%)
of 14 tumours showing overexpression of the c-erbB-2
oncogene compared with 19 (37%) of 51 c-erbB-2 negative
tumours (Wright et al., 1991). These data suggest that by
assessing steroid and peptide hormone receptor status it may
be possible to define subgroups of patients who are unlikely
to respond to endocrine therapy. The relationship between
overexpression of oncogenes such as c-erbB-1 (EGFR) and
c-erbB-2 and chemotherapy response has yet to be fully
investigated.
A wide variety of mechanisms have been implicated in the
aetiology of resistance to cytotoxic therapy, including the
detoxifying action of enzymes such as the glutathione S-
transferase (GSTs) (Harris, 1990). The GSTs are a family of
multifunctional enzymes which catalyse conjugation of
electrophilic substrates (including some chemotherapeutic
drugs) with glutathione (Boyer, 1989; Waxman, 1990). Mam-
malian GSTs are subdivided into three cytosolic forms
(designated alpha, mu and pi) and a microsomal form, each
with differing structural and functional characteristics (Man-
nervik et al., 1985; Morgenstern et al., 1985). That GSTs
might be involved in drug resistance is indicated by studies
showing an association between raised levels of GSTs and
acquisition of the resistant phenotype in cell lines (Wolf et
al., 1990; Waxman, 1990). GSTs have been demonstrated in
normal and neoplastic human breast tissue by a variety of
methods (Di Ilio et al., 1985; Howie et al., 1989; Lewis et al.,
1989; Moscow et al., 1988) and, using an immunohisto-
chemical technique, we have previously described the fre-
quency of expression and cellular localisation of the three
cytosolic isoenzymes in breast cancers (Cairns et al., 1991).
In the current study the pre-treatment expression of c-
erbB-2 and cytosolic GST isoenzymes has been correlated
with response to therapy in a series of breast tumours from
patients entered in a trial of mitoxantrone as first-line
chemotherapy for advanced breast cancer.
Patients and methods
The 68 patients studied has been entered in a trial comparing
short-term and continuous mitoxantrone therapy in advanced
breast cancer, the details of which have been described
elsewhere (Harris et al., 1990). The median patient age at
diagnosis was 50 years (range 25-76 years). None of the
patients had previously received chemotherapy. All had been
given endocrine therapy which had failed, or they had
visceral disease unlikely to respond to endocrine treatment.
Mitoxantrone was given as intravenous boluses (14 mg m-2)
every 3 weeks for four courses. Criteria for a response were
those of the International Union against Cancer (UICC)
(Hayward et al., 1977).
Sections (3 microns thick) were cut from formalin-fixed,
paraffin-embedded blocks of mastectomy or lumpectomy
specimens from the 68 patients. The immunohistochemical
methods used to determine expression of c-erbB-2 protein
and pi, alpha and mu class GSTs have been previously
described (Cairns et al., 1991). Staining for c-erbB-2 was
performed by an indirect immunoperoxidase method using
the monoclonal antibody NCL-CBl1 (Corbett et al., 1990),
and for GSTs by a peroxidase-antiperoxidase technique with
polyclonal GST antisera (Hall et al., 1990; Cairns et al.,
1991). For both methods the peroxidase reaction was
developed using diaminobenzidine. A positive control section
was included with each staining run: this was either a c-erbB-
2 positive breast cancer (NCL-CB11), human or rat liver
(GST pi or mu) or human kidney (GST alpha). Negative
controls were prepared by staining duplicate sections of each
tumour but omitting the primary antibody.
In scoring the sections an assessment was made both of the
proportion of cells staining (0, 1-10%, 11-50%, 51-100%)
and of the staining intensity (weak = +, moderate = + +,
strong = + + +). A tumour was scored as c-erbB-2 positive
if more than 50% of the tumour cells showed moderate or
strong membrane staining; these criteria define a subgroup of
breast cancer patients with earlier relapse and shorter overall
survival (Wright et al., 1989). Tumours staining with GST
antibodies show a combination of nuclear and cytoplasmic
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staining (Cairns et al., 1991); tumours showing any staining
with these antibodies were scored as positive.
A haematoxylin and eosin stained section of each tumour
was examined to determine tumour type (64 invasive ductal,
three invasive lobular, one invasive papillary).
Relationships between variables were examined by the chi-
squared test or Fisher's exact test, as appropriate. Survival
curves were prepared by the life table method, with com-
parisons between curves by the logrank test (Peto et al.,
1977).
Results
Response to mitoxantrone
The overall objective response rate was 38% (one complete
response, 25 partial responses). Twelve patients (18%) had
stable disease for 3 months or longer and 30 (44%) progres-
sive disease. The partial response and stable disease groups
behaved similarly, showing no significant differences in sur-
vival from diagnosis, from first relapse or from start of
treatment, or in time to disease progression on treatment
(Harris et al., 1990). Therefore, in correlating response with
c-erbB-2 or GST expression, patients with stable disease were
combined with those showing objective responses. Analysing
the objective responders separately produced essentially
similar results and did not alter the conclusions drawn.
c-erbB-2 expression
Sixteen tumours (23%) were scored c-erbB-2 positive. Com-
pared to patients with c-erbB-2 negative tumours, those with
positive tumours had a lower response rate (50% vs 58%;
Table I) and shorter duration of response (median response
duration 17 wk (range 3-55 wk) vs 29 wk (range 8-94 wk);
Figure 1), but these associations were not statistically
significant. Survival from the start of treatment was
significantly shorter for patients with c-erbB-2 positive
tumours (Figure 2). Figures 1 and 2 were prepared using
data from 67 patients since one patient with static disease
and a c-erbB-2 positive tumour was lost to follow up.
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Survival from start of treatment, stratified by c-erbB-2
GSTexpression
In a previous study GST pi was found to be expressed
consistently by normal mammary epithelium (which thus
functions as a useful internal positive control) and often by
tumour stroma (Cairns et al., 1991). Eight tumours in the
current series showed a complete lack of staining with all
three GST isoenzymes, including an apparent absence of
GST pi expression by normal epithelium and tumour stroma;
this was regarded as indicative of post-resection enzyme
Table I Response to mitoxantrone therapy
expressi
degradation, possibly related to ineffective fixation, and as a
precaution these tumours were excluded from correlations of
GST expression with treatment response. (c-erbB-2 appears
to be stable for at least 24 h following resection (Ong et al.,
1990) and four of these eight tumours were c-erbB-2
positive). Occasional tumours showing excessive stromal
background staining were also regarded as unevaluable.
No correlation was apparent between expression of the
individual GST isoenzymes and response to mitoxantrone
related to c-erbB-2 and GST isoenzyme
Complete or Static Progressive No. of
partial response disease disease evaluable cases
c-erbB-2 - 21 9 22 68
+ 5 3 8
GSTpi - 11 7 12 59
+ 12 5 12
GSTpi -/weak + 18 9 17 59
strong + 5 3 7
GSTpi - 7 6 12 57
(epithelium and/or
stroma + 16 6 10
GSTalpha - 20 11 20 60
+ 3 1 5
GSTmu - 13 6 16 56
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therapy. The GST pi data were further analysed by including
in the pi positive group: (a) only those patients with the most
intensely staining tumours (i.e., moderate or strong staining
of more than 50% of the tumour cells); or (b) those with
tumours showing positively staining tumour epithelium and/or
stroma (on the basis that stromal fibroblasts or inflammatory
cells may contribute to metabolism ofmitroxantrone). Again,
neither of these groups showed an association with response
status. The GST-response data are summarised in the Table.
There was no correlation between GST expression (pi, alpha
or mu) and duration of response to treatment (data not
shown).
Discussion
In the treatment of breast cancer, the synthetic anthra-
cenedione mitoxantrone shows comparable antitumour
activity to doxorubicin but appears to be less toxic
(Shenkenberg & van Hoff, 1986; Henderson et al., 1989).
Objective responses are seen in about 30% of patients with
advanced breast cancer, but as for other cytotoxic agents
there is no reliable method of identifying these patients
before treatment. The comparable efficacy of short-term and
continuous mitoxantrone therapy suggests that resistance
mechanisms are in place before, or appear early in the course
of, treatment (Harris et al., 1990). Although there is evidence
that mitoxantrone is a substrate for GSTs (Wolf et al., 1986),
the present study did not demonstrate a significant relation-
ship between GST expression and response to mitoxantrone,
suggesting that alone cytosolic GSTs do not play an impor-
tant role in mediating resistance to mitoxantrone in breast
cancer. It is of course possible that response to mitoxantrone
and similar agents is dependent on the interrelationships
betwen GSTs and other mechanisms involved in the cellular
handling and metabolism of cytotoxic drugs, and what may
therefore be required are tumour profiles which take into
account a number of these different mechanisms. For exam-
ple, P-glycoprotein expression occurs in a proportion of
breast cancers (Schneider et al., 1989; Wishart et al., 1990)
and has been associated with lack of response to combina-
tion chemotherapy (Verrelle et al., 1991). Keith et al. (1990)
were able to demonstrate a relationship between levels of
mdrl mRNA and sensitivity to doxorubicin in breast cancer
cells grown in short term culture; GST pi mRNA levels were
also assessed, but in this model did not appear to improve
the ability to predict doxorubicin sensitivity. The present
study contained insufficient numbers of patients to determine
the possible importance of the combined effects of GSTs and
c-erbB-2.
Using immunohistochemistry it is possible to demonstrate
the tissue distribution of a particular antigen, and we have
previously reported that GST pi may be present in both
neoplastic and non-neoplastic components of breast cancers
(Cairns et al., 1991). Expression of GST pi by stromal or
inflammatory cells did not appear to influence response to
mitoxantrone, but it is apparent that immunohistochemistry
can be useful when attempting to separate the role played by
different cell types in complex tissues such as epithelial
cancers with a large stromal component.
Recent studies indicate that growth factor receptors may
be directly involved in the development and progression of
breast cancer. Overexpression of either EGFR or c-erbB-2 is
associated with shorter relapse-free and overall survival
(Sainsbury et al., 1987; Lewis et al., 1990; Perren, 1991) and
also with lack of response to endocrine therapy (Nicholson et
al., 1989; Wright et al., 1991), suggesting that the correspon-
ding ligands may override the effects of endocrine therapy on
tumour cell proliferation. However, overexpression of c-erbB-2
is also associated with high nuclear grade (Perren, 1991) and
high S phase fraction (Borg et al., 1991), parameters which
have been correlated with likelihood of response to chemo-
therapy (Remvikos et al., 1989; Fisher et al., 1986). One
might then predict that c-cerbB-2 positive tumours would be
less resistant to chemotherapy, but in a recent study of
node-negative patients receiving adjuvant therapy c-erbB-2
overexpression was associated with drug resistance in a group
of 'poor-risk' (large and/or ER-negative) tumours (Allred et
al., 1990). We found overexpressing tumours showed a trend
towards a lower response rate and a shorter response dura-
tion compared with c-erbB-2 negative tumours. Further,
overexpression was related to reduced survival following start
of chemotherapy, in keeping with previous reports (Wright et
al., 1989; Borg et al., 1991) showing a correlation with
shorter post-relapse survival. That survival was poorer in the
c-erbB-2 positive group despite response to mitoxantrone
suggests that this subgroup of patients should perhaps be
selected for a more intense treatment regimen. These observa-
tions and the finding that patients with c-erbB-2 positive
tumours appear unlikely to benefit from endocrine therapy
on relapse (Wright et al., 1991) indicate a possible role for
growth factor receptor status in directing treatment strategies
for individual patients.
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